Annex

The following entry shall be added at the end of the table in Annex I to Directive 91/414/EEC:

Further details on identity and specification of active substance are provided in the review report.
No	Common name, identification numbers	IUPAC name	Purityf1	Entry into force	Expiration of inclusion	Specific provisions
‘323	Bromuconazole CAS No: 116255-48-2 CIPAC No: 680	1-[(2RS,4RS:2RS,4SR)-4-bromo-2-(2,4-dichlorophenyl)tetrahydrofurfuryl]-1H-1,2,4-triazole	≥ 960 g/kg	1 February 2011	31 January 2021	PART A Only uses as fungicide may be authorised. PART B For the implementation of the uniform principles of Annex VI, the conclusions of the review report on bromuconazole, and in particular Appendices I and II thereof, as finalised in the Standing Committee on the Food Chain and Animal Health on 23 November 2010 shall be taken into account. In this overall assessment, Member States shall pay particular attention to: operator’s safety and ensure that conditions of use prescribe the application of adequate personal protective equipment where appropriate, protection of aquatic organisms. Conditions of authorisation shall include risk mitigation measures, where appropriate, such as adequate buffer zones. The Member States concerned shall ensure that the applicant presents to the Commission: further information on residues of triazole derivative metabolites (TDMs) in primary crops, rotational crops and products of animal origin, information to further address the long-term risk to herbivorous mammals. They shall ensure that the applicant at whose request bromuconazole has been included in this Annex provides such confirmatory information to the Commission by 31 January 2013 at the latest. The Member States concerned shall ensure that the applicant submits to the Commission further information addressing the potential endocrine disrupting properties of bromuconazole within two years after the adoption of the OECD test guidelines on endocrine disruption or, alternatively, of Community agreed test guidelines.’